What Arecor does
Arecor Limited is a privately-owned biopharmaceuticals company developing superior diabetes care through the application of its innovative formulation technology platform.
Arecor is leveraging this platform to:
(i) develop a portfolio of proprietary products for diabetes care
(ii) deliver superior reformulations of its partners proprietary products.
It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.
In March, Arecor extended a multi-product collaboration with a US-based biotech company to develop products for oncology and a rare genetic orphan condition.
Under the collaboration, Arecor said it will leverage its Arestat technology to develop liquid formulations of two proprietary novel products, while its partner is currently funding the development work and has an option to acquire the formulations and associated intellectual property under separate milestone-bearing licenses at pre-agreed financial terms.
In February, the firm inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.
The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.
Later that month, the company said it had achieved an important second, contractual milestone with one of its pharmaceutical partners.
The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
In accordance with the license agreement, the partner has rights to further develop, manufacture and commercialise a novel, superior formulation of a biosimilar product, which was developed by Arecor using its proprietary Arestat platform.
In January, Arecor also signed an agreement with FTSE 100 firm Hikma Pharmaceuticals PLC (LON:HIK) to develop a new, ready-to-use injectable medicine.
The new product, to be announced prior to launch, will use Arecor’s Arestat drug formulation technology and is expected to be submitted to the US Food and Drug Administration for regulatory approval in 2021.
In December, Arecor hailed the successful completion of a phase I trial for its ultra-rapid acting insulin for diabetics, which it said had a “favourable profile” when compared with standard treatments.
The company said that its candidate, AT247, had finished a phase I double-blind, randomised study at The Medical University of Graz and Joanneum Research in Austria, in which it was measured against two other insulins on the market, NovoRapid and Fiasp.
Watch the interview
What the boss says
"This multi-collaboration with a fast growing US biotech company demonstrates the adaptability of the Arestat platform”, said Arecor chief executive Sarah Howell of the group's collaboration with a US-based biotech company to develop products for oncology and a rare genetic orphan condition.
“Not only do these key products represent Arestat’s ability to support the development of clinical stage assets across a range of therapeutic areas, but also demonstrate the potential of the technology to deliver superior liquid formulations of novel format proteins, further expanding and advancing the application of Arecor’s expertise across the spectrum of product development”, she added.